Lisa Rojkjaer
Net Worth
Last updated:
What is Lisa Rojkjaer net worth?
The estimated net worth of Dr. Lisa Rojkjaer is at least $1,906,035 as of 27 Feb 2023. He owns shares worth $470 as insider, has earned $50,765 from insider trading and has received compensation worth at least $1,854,800 in Viracta Therapeutics, Inc..
What is the salary of Lisa Rojkjaer?
Dr. Lisa Rojkjaer salary is $463,700 per year as Chief Medical Officer in Viracta Therapeutics, Inc..
How old is Lisa Rojkjaer?
Dr. Lisa Rojkjaer is 59 years old, born in 1966.
What stocks does Lisa Rojkjaer currently own?
As insider, Dr. Lisa Rojkjaer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Viracta Therapeutics, Inc. (VIRX) | Chief Medical Officer | 48,087 | $0.01 | $470 |
What does Viracta Therapeutics, Inc. do?
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Lisa Rojkjaer insider trading
Viracta Therapeutics, Inc.
Dr. Lisa Rojkjaer has made 7 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 2,156 units of VIRX stock worth $3,624 on 27 Feb 2023.
The largest trade he's ever made was exercising 34,750 units of VIRX stock on 11 May 2021. As of 27 Feb 2023 he still owns at least 48,087 units of VIRX stock.
Viracta Therapeutics key executives
Viracta Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Ivor Royston M.D. (79) Chief Executive Officer, Pres & Director
- Dr. Lisa Rojkjaer (59) Chief Medical Officer
- Mr. Daniel R. Chevallard (45) Chief Financial Officer, Chief Operating Officer & Sec.